查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004211

细胞和基因治疗市场：2026-2032年全球市场预测（按治疗方法、给药途径、治疗领域、应用和最终用户划分）

Cell & Gene Therapy Market by Therapy Type, Delivery Method, Therapeutic Areas, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，细胞和基因治疗市场价值将达到 194.7 亿美元，到 2026 年将成长至 229.8 亿美元，到 2032 年将达到 713.8 亿美元，复合年增长率为 20.39%。

主要市场统计数据
基准年 2025 194.7亿美元
预计年份：2026年 229.8亿美元
预测年份 2032 713.8亿美元
复合年增长率 (%) 20.39%

简明策略框架阐述了科学进步、製造复杂性增加以及政策趋势如何重塑细胞和基因治疗生态系统。

细胞和基因治疗生态系统正处于转折点，科学突破与营运和商业的复杂性交织在一起。载体工程、基因编辑精准性和过继性细胞技术的进步已将曾经的理论治疗方法转变为临床现实。同时，相关人员面临着生产瓶颈、专业的低温运输物流以及不断变化的监管预期，这需要产业界、学术界和服务供应商协调应对。

随着技术、营运、监管和商业因素的交汇，细胞和基因治疗领域的相关人员正在面临哪些新的策略挑战？

细胞和基因疗法领域的格局正在以多种相互关联的方式转变，重新定义竞争优势。技术进步提高了治疗的特异性和持久性，而基因编辑平台和载体设计的创新则减少了脱靶效应，并拓展了治疗应用范围。同时，生产製造也从客製化的小批量生产流程转向更标准化、模组化的方法，优先考虑稳健性、可重复性和成本控制。这种营运模式的演变使得新一代的契约製造组织（CMO）和平台供应商能够提供可扩展的解决方案。

评估近期关税政策变化对先进治疗方法供应链、製造本地化和风险管理策略的多方面影响。

美国在2025年实施的关税调整将为细胞和基因治疗产业带来新的复杂性，尤其因为该产业依赖来自世界各地的原材料和跨境生产链。试剂、特殊原料和某些生物製药成分的关税可能会迫使采购团队重新评估其供应商关係和库存策略。对于依赖少数关键供应商的企业而言，关税将奖励选择替代供应商，并将部分供应链本地化，以降低成本波动和海关延误带来的影响。

基于细分市场的分析揭示了治疗方法、给药途径、适应症、用例和最终用户概况如何影响商业性和营运选择。

深入的市场区隔能够清楚展现临床潜力与实际营运的交会点，帮助领导者精准地分配资源。依治疗方法类型分析市场，可以揭示清晰的研发和生产路径。细胞疗法分为干细胞疗法和T细胞疗法，其中干细胞疗法可细分为造血干细胞疗法和间间质干细胞疗法。 T细胞疗法则分为CAR-T细胞疗法和T细胞受体疗法。基因疗法又引入了另一个细分维度：体外基因疗法和基因治疗，二者各自拥有独特的载体、递送方法和安全性特征，这些因素都会影响研发进度和监管互动。

区域战略趋势和基础设施因素对确定临床开发、生产能力和市场进入倡议具有重要意义。

区域趋势对整个细胞和基因治疗领域的研发策略、监管环境和供应链设计都具有深远的影响。在美洲，创新丛集汇聚了临床专业知识、先进的製造能力和创业投资资金生态系统，从而支持快速转化研究；同时，相关人员必须应对复杂的支付方环境和各州不同的政策。该地区的监管环境既严格强调临床证据，又允许有条件核准的早期准入途径。在营运方面，接近性关键学术机构有利于建立伙伴关係，从而加速早期临床试验。

专注于整合、平台专业化和卓越服务的企业策略如何重塑其在整个细胞和基因治疗价值链中的竞争地位。

企业层面的策略正趋向一系列核心能力，这些能力将决定先进疗法领域的赢家和输家。主要企业正在投资垂直整合的能力，涵盖药物发现、载体和细胞工程、製程开发以及商业化规模生产，同时保持灵活的伙伴关係，以实现产能的快速扩张。其他企业则专注于平台技术，例如模组化生产系统、高效价载体生产和封闭式细胞处理系统，并透过许可或以合约服务形式运作这些技术，利用规模和可重复性创造价值。

领导者可采取的策略重点，以加强供应链韧性、扩大生产规模、协调监管策略并加快支付方采用。

产业领导者应优先考虑一系列切实可行的倡议，将科学优势转化为永续的商业性成功。首先，加强与供应商的伙伴关係，并采用双重采购策略来确保临床供应的连续性，同时降低地缘政治因素和关税波动带来的风险。其次，投资模组化生产能力和自动化技术可以减少批次间差异，提高单位成本，并扩大内部生产和契约製造伙伴关係的选择范围。此外，制定清晰的监管沟通计划，纳入真实世界数据策略和核准后数据收集，将有助于加快与支付方的对话，并支持基于结果的合约模式。

严谨的混合研究途径，结合与关键相关人员的访谈、监管和专利分析以及流程图绘製，检验了营运和策略见解。

本分析整合了多方面的证据，建构了细胞和基因治疗领域当前趋势的稳健且可重复的视图。主要调查包括对药物研发机构、临床开发团队、生产和供应链负责人、监管事务专家以及支付方的结构化访谈。次要调查则利用了同行评审文献、公开的监管指南、临床试验註册资讯、企业资讯披露资讯、专利申请以及物流和低温运输的研究，从多个角度检验了营运和科学趋势。

一项综合评估，将科学进步与营运准备和商业性途径联繫起来，以确保患者能够持续获得治疗，并实现业务的可持续永续性。

细胞和基因治疗领域已进入一个新阶段，在这个阶段，不仅科学创新，策略执行也将决定哪些治疗方法能产生持久的临床和商业性影响。科学进步不断拓展可治疗疾病的范围，并提高治疗的精准度，但要将这些疗法惠及患者，需要各方齐心协力，共同扩大生产规模、构建稳健的供应链、确保合规性，并为支付方提供充分的证据。那些积极建立稳健的供应商网络、采用模组化生产和数位化品管体系，并以可信的、基于真实世界证据的故事与支付方沟通的领导者，将更有能力将临床成功转化为广泛的患者群体。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法的细胞和基因治疗市场

  • 细胞疗法
    • 干细胞疗法
      • 造血干细胞疗法
      • 间质干细胞疗法
    • T细胞疗法
      • CAR-T细胞疗法
      • 基于T细胞受体（TCR）
  • 基因治疗
    • 体外基因治疗
    • 体内基因治疗

第九章：细胞与基因治疗市场：依给药方式划分

  • 肌肉内部
  • 静脉

第十章：按治疗领域分類的细胞和基因治疗市场

  • 循环系统
    • 郁血性心臟衰竭
    • 缺血性心臟疾病
  • 代谢性疾病
    • 糖尿病
    • 肥胖
  • 神经系统疾病
    • 阿兹海默症
    • 亨丁顿舞蹈症
    • 多发性硬化症
    • 帕金森氏症
    • 脊髓损伤
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 淋巴瘤
    • 固态肿瘤
  • 眼科

第十一章 细胞与基因治疗市场：依应用领域划分

  • 临床应用
    • 疾病预防
    • 疾病治疗
  • 研究与开发

第十二章 细胞与基因治疗市场：依最终用户划分

  • 学术和研究机构
    • 私人研究机构
    • 大学
  • 医院和诊所

第十三章 细胞与基因治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 细胞与基因治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 细胞与基因治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国细胞与基因治疗市场

第十七章：中国细胞与基因治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • AGC Inc.
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cellectis SA
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Mustang Bio, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • REGENXBIO Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Shoreline Biosciences
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market was valued at USD 19.47 billion in 2025 and is projected to grow to USD 22.98 billion in 2026, with a CAGR of 20.39%, reaching USD 71.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.47 billion
Estimated Year [2026] USD 22.98 billion
Forecast Year [2032] USD 71.38 billion
CAGR (%) 20.39%

A concise strategic framing of how scientific advances, manufacturing complexity, and policy dynamics are reshaping the cell and gene therapy ecosystem

The cell and gene therapy ecosystem stands at an inflection point where scientific breakthroughs are converging with operational and commercial complexity. Advances in vector engineering, gene editing precision, and adoptive cell technologies have moved previously theoretical interventions into clinical reality. At the same time, stakeholders are grappling with manufacturing bottlenecks, specialized cold-chain logistics, and evolving regulatory expectations that require coordinated responses across industry, academia, and service providers.

This executive summary distills the strategic implications of these shifts for leaders who must balance innovation with scale. It synthesizes emerging technology trajectories, supply chain vulnerabilities, payer and health system dynamics, and the policy environment shaping cross-border activity. The intent is to equip decision-makers with a clear narrative and practical lenses to evaluate near-term operational priorities and medium-term strategic options. By linking technical advances to commercial and regulatory realities, the analysis clarifies where investments and partnerships are most likely to deliver differentiated value.

Throughout this summary, emphasis is placed on executable insights rather than abstract trends, enabling teams to align R&D roadmaps, manufacturing investments, and go-to-market strategies with the most consequential drivers of success in the current landscape.

How converging technological, operational, regulatory, and commercial forces are creating new strategic imperatives for cell and gene therapy stakeholders

The landscape for cell and gene therapies is transforming along multiple, interlocking dimensions that together redefine competitive advantage. Technological advances are improving specificity and durability of treatments, with innovations in gene-editing platforms and vector design reducing off-target effects and broadening therapeutic applicability. Concurrently, manufacturing is transitioning from bespoke, small-batch processes to more standardized modular approaches that prioritize robustness, reproducibility, and cost control. This operational evolution is enabling a new class of contract manufacturing organizations and platform providers to offer scalable solutions.

Regulatory frameworks are adapting to accommodate rapid scientific progress, increasingly emphasizing real-world evidence, adaptive trial designs, and lifecycle oversight models. Payer engagement is also maturing, with outcome-based contracting and installment payment structures emerging as viable mechanisms to bridge high upfront costs and long-term clinical value. Geopolitical and trade dynamics are prompting sponsors to reassess supply chain strategies, driving interest in regional manufacturing and supplier diversification. As a result, partnerships and network orchestration are becoming central strategic levers: companies that can integrate discovery, development, and delivery across a distributed value chain while retaining control of core intellectual property will gain advantage.

Taken together, these shifts favor organizations that can couple scientific excellence with operational discipline, regulatory acuity, and commercial creativity, enabling therapies to move from promising science to sustainable patient access.

Assessing the multifaceted effects of recent tariff policy changes on supply chains, manufacturing localization, and risk management strategies in advanced therapies

The implementation of tariff changes in the United States in 2025 introduces a new layer of complexity for the cell and gene therapy sector, particularly because the industry relies on globally sourced inputs and cross-border manufacturing chains. Tariffs on reagents, specialized raw materials, and certain biologics components can drive procurement teams to re-evaluate supplier relationships and inventory strategies. For organizations dependent on a narrow set of critical suppliers, tariffs increase the incentive to qualify alternate suppliers or to localize portions of the supply chain to mitigate cost volatility and customs-related delays.

Beyond direct cost impacts, tariff policy influences capital allocation decisions related to manufacturing geography. Firms are increasingly weighing the trade-offs between building regional production capacity and maintaining centralized facilities that benefit from scale. Tariffs can accelerate regionalization by making domestic or nearshore production economically more attractive, but they can also fragment supply networks and amplify the need for redundant validation streams. Logistics flows are likewise affected: customs processing times and additional documentation requirements can stress cold-chain integrity for temperature-sensitive products, prompting greater investment in contingency transport options and quality monitoring across transit.

Strategically, the tariff environment will push companies to deepen upstream engagement with suppliers, to pursue integrated sourcing strategies that combine contractual protections with dual sourcing, and to enhance scenario planning that models policy shifts. For regulators and industry associations, the implications include a greater call for dialogue to ensure that trade measures do not inadvertently impede patient access or innovation by introducing excessive administrative burden. In sum, tariffs shape not only cost structures but also the architecture of global manufacturing and risk management for cell and gene therapy programs.

A segmentation-driven synthesis revealing how therapy modality, delivery route, therapeutic indication, application use case, and end-user profile shape commercial and operational choices

Insightful segmentation clarifies where clinical promise intersects with operational realities and allows leaders to prioritize resources with precision. When the market is parsed by therapy modality, distinct development and manufacturing pathways emerge: cell therapies divide into stem cell approaches and T cell-based approaches, with stem cell therapies further delineated into hematopoietic stem cell therapies and mesenchymal stem cell therapies, while T cell strategies separate into CAR T cell therapy and T cell receptor-based approaches. Gene therapies introduce another axis of differentiation, distinguishing ex vivo gene therapy from in vivo gene therapy, each carrying unique vector, delivery, and safety profiles that influence development timelines and regulatory interactions.

Delivery method segmentation underscores differences in clinical implementation and patient management, with intramuscular and intravenous approaches presenting divergent requirements for administration training, infusion capacity, and monitoring. Therapeutic area segmentation highlights how disease biology drives modality choice and commercial pathways: cardiovascular applications focus on congestive heart failure and ischemic heart disease, metabolic disorder efforts emphasize diabetes and obesity, neurological programs concentrate on conditions such as Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, and spinal cord injuries, and oncology initiatives pivot across hematological malignancies, lymphomas, and solid tumors. Application-based segmentation separates clinical applications from research and development activities, with the former further parsed into disease prevention and disease treatment, reflecting differing regulatory endpoints and payer expectations. Finally, end-user segmentation recognizes divergent purchasing and adoption dynamics between academic and research institutes and hospitals and clinics, with academic and research institutes further distinguished into private research labs and universities that shape investigator-initiated studies and translational pipelines.

Understanding these overlapping segments enables more targeted clinical trial design, manufacturing footprint planning, and commercialization strategies by aligning technical capabilities with the specific regulatory, clinical, and payer pathways associated with each segment.

Regional strategic dynamics and infrastructure considerations that determine where to locate clinical development, manufacturing capacity, and market access initiatives

Regional dynamics exert a powerful influence on development strategies, regulatory approaches, and supply chain design across the cell and gene therapy landscape. In the Americas, innovation clusters concentrate clinical expertise, advanced manufacturing capabilities, and venture funding ecosystems that support rapid translational activity, but stakeholders must manage complex payer landscapes and heterogeneous state-level policies. The regulatory environment in the region reflects an emphasis on rigorous clinical evidence combined with early access pathways that can facilitate conditional approvals; operationally, proximity to major academic centers supports partnerships that accelerate early-phase trials.

The Europe, Middle East & Africa region presents a mosaic of regulatory models and reimbursement systems. While some European jurisdictions offer collaborative assessment frameworks and health technology assessment pathways that reward long-term value, others require extensive local evidence generation. The region's manufacturing landscape is evolving with investments in capacity and specialized service providers, yet companies navigating this geography must reconcile cross-border regulatory variances and diverse healthcare funding mechanisms. Capacity-building initiatives and public-private partnerships are increasingly important levers to expand access in parts of the region where infrastructure remains nascent.

Asia-Pacific combines rapidly maturing clinical trial capabilities with ambitious national strategies to become hubs for biotechnology manufacturing and commercialization. Governments across the region are investing in biotechnology infrastructure, streamlined regulatory pathways for advanced therapies, and talent development programs. This creates both opportunity and complexity: sponsors can access large patient populations and lower development costs, but must also adapt to different regulatory expectations, local manufacturing requirements, and market access criteria.

Attuning strategy to these regional differences is essential for aligning trial design, manufacturing placement, and commercial access plans with local regulatory realities and payer expectations.

How company strategies focused on integration, platform specialization, and service excellence are reshaping competitive positioning across the cell and gene therapy value chain

Company-level strategies are converging around a set of core capabilities that differentiate winners from also-rans in the advanced therapy arena. Leading organizations are investing in vertically integrated capabilities that span discovery, vector and cell engineering, process development, and commercial-scale manufacturing, while also maintaining flexible partnerships that allow rapid capacity expansion. Others are specializing in platform technologies-such as modular manufacturing systems, high-titer vector production, or closed-system cell processing-that they can license or operate as contract services, thereby capturing value through scale and reproducibility.

Service providers and contract manufacturers are playing an increasingly strategic role by offering end-to-end solutions that reduce time-to-clinic for sponsors and lower technical risk. Companies that excel in quality systems, regulatory compliance, and supply chain orchestration are securing long-term relationships with sponsors by guaranteeing throughput and minimizing release delays. Meanwhile, developers are differentiating through clinical program design, biomarker-driven patient selection, and payer engagement strategies that translate clinical benefit into credible health economic narratives.

Investor and corporate development activity is focused on capabilities that address the industry's most pressing bottlenecks: scalable vector production, automation of cell handling, robust analytics for potency and comparability, and digitized batch record systems. Across these company archetypes, success correlates with the ability to demonstrate reproducible manufacturing, credible clinical outcomes, and a commercialization plan that accounts for reimbursement complexity and international market entry barriers.

Actionable strategic priorities for leaders to strengthen supply resilience, scale manufacturing, align regulatory strategy, and accelerate payer adoption

Industry leaders should prioritize a set of pragmatic actions to translate scientific advantage into durable commercial success. First, strengthening supplier partnerships and dual sourcing for critical inputs will mitigate exposure to geopolitical and tariff-driven disruptions while enabling continuity of clinical supply. Simultaneously, investing in modular manufacturing capabilities and automation can reduce batch variability and improve unit economics, creating optionality for both in-house production and contract manufacturing partnerships. In parallel, establishing clear regulatory engagement plans that incorporate real-world evidence strategies and post-approval data collection will accelerate payer conversations and support outcome-based contracting models.

Operationally, organizations should accelerate digitalization of quality systems and batch analytics to enable more predictive manufacturing control and faster regulatory submissions. Cross-functional alignment between R&D, manufacturing, and commercial teams is essential: integrated project governance that links clinical milestones to manufacturing readiness and market access requirements will reduce delays during transition to late-stage development. Collaboration with healthcare providers to design feasible administration pathways-particularly for complex cell therapies requiring specialized infusion centers-will ensure patient access and streamline adoption.

Finally, scenario-based strategic planning that models tariff outcomes, regulatory shifts, and capacity constraints will help leadership teams prioritize investments and partnership choices. By combining supply chain resilience, manufacturing scalability, regulatory foresight, and payer-focused evidence generation, industry leaders can de-risk development pathways and create sustainable routes to patient access.

A rigorous mixed-methods research approach that combines primary stakeholder interviews, regulatory and patent analysis, and process mapping to validate operational and strategic insights

This analysis synthesizes multiple evidence streams to construct a robust and reproducible view of current dynamics in the cell and gene therapy sector. Primary research included structured interviews with stakeholders across discovery organizations, clinical development teams, manufacturing and supply chain leaders, regulatory affairs experts, and payers. Secondary research drew on peer-reviewed literature, publicly available regulatory guidance, clinical trial registries, company disclosures, patent filings, and logistics and cold-chain studies to triangulate operational and scientific trends.

Analytical methods included process mapping of manufacturing workflows to identify common bottlenecks, comparative regulatory analysis to surface jurisdictional variances, and qualitative coding of expert interviews to highlight recurring strategic themes. Scenario analysis was employed to evaluate the operational implications of tariff changes and supply chain disruptions. Where appropriate, findings were validated through cross-checks with subject matter experts to reduce bias and ensure technical accuracy. Limitations include the pace of innovation in the field, which can create rapid shifts in capability and regulation, and the variability of proprietary manufacturing processes that limit direct comparability across all developers.

Despite these constraints, the methodology emphasizes triangulation and expert validation to produce insights that are actionable for strategic decision-making, investment evaluation, and operational planning.

Concluding synthesis that links scientific progress to operational readiness and commercial pathways for achieving durable patient access and business sustainability

The cell and gene therapy field is entering a phase where strategic execution, not just scientific novelty, will determine which therapies achieve lasting clinical and commercial impact. Scientific advances continue to expand the range of treatable conditions and improve the precision of interventions, yet the path to patients demands concerted attention to manufacturing scale-up, supply chain robustness, regulatory alignment, and payer evidence generation. Leaders who proactively build resilient supplier networks, adopt modular manufacturing and digital quality systems, and engage payers with credible real-world evidence narratives will be best positioned to translate clinical success into broad patient access.

The interplay of regional regulatory approaches, tariff dynamics, and commercial models means that global strategies must be flexible and locally adapted. Organizations that blend platform investments with smart partnerships and that apply scenario planning to geopolitical and policy changes will reduce execution risk. Above all, integrating scientific, operational, and commercial planning across the organization will accelerate transitions from demonstration to widespread adoption, ensuring therapies reach the patients who need them while maintaining sustainable business models.

Taken together, these priorities offer a practical roadmap for converting innovation into impact in a competitive and rapidly evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Market, by Therapy Type

  • 8.1. Cell Therapy
    • 8.1.1. Stem Cell Therapies
      • 8.1.1.1. Hematopoietic Stem Cell Therapies
      • 8.1.1.2. Mesenchymal Stem Cell Therapies
    • 8.1.2. T Cell Therapy
      • 8.1.2.1. CAR T Cell Therapy
      • 8.1.2.2. T Cell Receptor (TCR)-based
  • 8.2. Gene Therapy
    • 8.2.1. Ex Vivo Gene Therapy
    • 8.2.2. In Vivo Gene Therapy

9. Cell & Gene Therapy Market, by Delivery Method

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Cell & Gene Therapy Market, by Therapeutic Areas

  • 10.1. Cardiovascular
    • 10.1.1. Congestive Heart Failure
    • 10.1.2. Ischemic Heart Disease
  • 10.2. Metabolic Disorders
    • 10.2.1. Diabetes
    • 10.2.2. Obesity
  • 10.3. Neurological Disorders
    • 10.3.1. Alzheimer's Disease
    • 10.3.2. Huntington's Disease
    • 10.3.3. Multiple Sclerosis
    • 10.3.4. Parkinson's Disease
    • 10.3.5. Spinal Cord Injuries
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Lymphomas
    • 10.4.3. Solid Tumors
  • 10.5. Ophthalmology

11. Cell & Gene Therapy Market, by Application

  • 11.1. Clinical Applications
    • 11.1.1. Disease Prevention
    • 11.1.2. Disease Treatment
  • 11.2. Research & Development

12. Cell & Gene Therapy Market, by End User

  • 12.1. Academic & Research Institutes
    • 12.1.1. Private Research Labs
    • 12.1.2. Universities
  • 12.2. Hospitals & Clinics

13. Cell & Gene Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cell & Gene Therapy Market

17. China Cell & Gene Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Abeona Therapeutics Inc.
  • 18.7. Adaptimmune Therapeutics PLC
  • 18.8. AGC Inc.
  • 18.9. Alnylam Pharmaceuticals, Inc.
  • 18.10. American Gene Technologies Inc.
  • 18.11. Amgen Inc.
  • 18.12. AnGes, Inc
  • 18.13. Astellas Pharma Inc.
  • 18.14. Becton, Dickinson and Company
  • 18.15. Biogen Inc.
  • 18.16. Bluebird Bio, Inc.
  • 18.17. BridgeBio Pharma, Inc.
  • 18.18. Bristol-Myers Squibb Company
  • 18.19. C.H. Boehringer Sohn AG & Co. KG
  • 18.20. Cellectis SA
  • 18.21. CRISPR Therapeutics AG
  • 18.22. F. Hoffmann-La Roche AG
  • 18.23. Gilead Sciences, Inc.
  • 18.24. Intellia Therapeutics, Inc.
  • 18.25. Ionis Pharmaceuticals, Inc.
  • 18.26. Johnson & Johnson Services Inc.
  • 18.27. Kyowa Kirin Co., Ltd.
  • 18.28. Merck KGaA
  • 18.29. Moderna, Inc.
  • 18.30. Mustang Bio, Inc.
  • 18.31. Novartis AG
  • 18.32. Novo Nordisk A/S
  • 18.33. Pfizer, Inc.
  • 18.34. REGENXBIO Inc.
  • 18.35. Sangamo Therapeutics, Inc.
  • 18.36. Sarepta Therapeutics, Inc.
  • 18.37. Shoreline Biosciences
  • 18.38. Sibiono GeneTech Co. Ltd.
  • 18.39. Syncona Limited
  • 18.40. Thermo Fisher Scientific Inc.
  • 18.41. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY T CELL RECEPTOR (TCR)-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OBESITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HUNTINGTON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SPINAL CORD INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY LYMPHOMAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DISEASE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRIVATE RESEARCH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 283. GCC CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. GCC CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GCC CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS CELL & GENE THERAPY MARKET SIZE, BY STEM CELL THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS CELL & GENE THERAPY MARKET SIZE, BY T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS CELL & GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS CELL & GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS CELL & GENE THERAPY MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS CELL & GENE THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS CELL & GENE THERAPY MARKET SIZE, BY CLINICAL APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS CELL & GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS CELL & GENE THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MIL